Half: A prospective Multi-Centre phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitors' discontinuation after two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission.
Authors | |
---|---|
Year of publication | 2021 |
Type | Conference abstract |
MU Faculty or unit | |
Citation | |
Related projects: |